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Objective: This study assessed the excess healthcare expenditures and factors associated with it among community-
dwelling adults with thyroid cancer compared to non-cancer controls in the United States.
Method: A retrospective, cross-sectional, matched case-control study design was used by pooling multiple years of
Medical Expenditure Panel Survey (MEPS) data (2002–2012). The eligible study sample comprised of adults (age
18 years), who were alive during the calendar year and reported positive healthcare expenditure. The case
group consisted of adults with thyroid cancer only while the control group consisted of adults who did not have
any form of cancer. Total and subtypes of mean annual healthcare expenditures comprised the main study
outcome. We also calculated the total and subtypes of out-of-pocket (OOP) expenditures as well as OOP as a
percentage of household income. Ordinary Least Square (OLS) regressions on log-transformed expenditures were
conducted to elucidate the inﬂuence of different factors on healthcare expenditures among adults with thyroid
cancer.
Results: The yearly average total healthcare expenditures among adults with thyroid cancer was signiﬁcantly
higher compared to propensity score matched controls ($9,585 vs. $5,830, p < 0.001). Similar observations were
found in terms of inpatient, and outpatient expenditures. Functional status as well as comorbid conditions were
signiﬁcantly associated with excess expenditures. The yearly average total OOP expenditure for adults with
thyroid cancer was signiﬁcantly higher compared to matched controls ($1,425 vs. $974, p < 0.001), with major
differences observed in inpatient OOP ($178 vs. $24, p ¼ 0.003), outpatient OOP ($435vs. $256, p < 0.001), and
prescription OOP ($554 vs. $423, p < 0.001) expenditures. There was a signiﬁcant (p < 0.001) difference be-
tween the average OOP as a percentage of household income between adults with thyroid cancer (Mean: 7.54%,
S.E: 1.52%) and matched controls (Mean: 5.80%, S.E: 0.47%).
Conclusions: Our ﬁndings suggest that holistic care approach could be helpful to signiﬁcantly reduce the economic
burden in this population. Viable strategies such as limits on OOP costs are required to minimize this high OOP
burden among cancer survivors and their families.1. Introduction
Thyroid cancer is considered a fairly common type of cancer, with an
estimated 637,115 individuals having the disease in the United States
(US) in 2013 [1]. In 2016, the number of new thyroid cancer cases was
estimated to be 64,300 [1], and the overall incidence of thyroid cancer
was observed to increase 3% annually from 1974-2013 [2]. However, the
5-year survival for individuals with thyroid cancer was estimated to bea.edu (S. Bhattacharjee).
April 2019; Accepted 19 June 2
vier Ltd. This is an open access a98.1% (2006–2012) [1]. Moreover, recent data showed that thyroid
cancer has continuously increased in the last three decades all over the
world, which can be attributed to sharp rise of use of more sensitive
diagnostic procedures or a possible true increase due to the increased
population exposure to some recognized or unrecognized carcinogens
[3]. In addition, a recent report has projected the incidence of thyroid
cancer in 2030 to be the fourth most common cancer based on the de-
mographic changes, the average annual percentage changes in incidence019
rticle under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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A few recent studies have examined the burden of thyroid cancer in
ex-US settings [5, 6, 7, 8, 9]. However, despite the increase in incidence
of thyroid cancer, data on clinical and economic impact of thyroid cancer
care is lacking in the US. Only a handful of studies in US examined the
costs associated with thyroid cancer [10, 11, 12].It is crucial to estimate
the burden of this disease for an appropriate utilization of speciﬁc
treatment modalities and health care services in light of rising trends in
incidence. Using National Cancer Institute's (NCI) Surveillance, Epide-
miology, and End Results (SEER) 13 databases between 1992 -2009, a
thyroid cancer cost analysis study was published in 2013 [10]. This study
showed that the estimated lifetime cost for a hypothetical cohort of in-
dividuals with thyroid cancer is $34,723 per patient, and ranged from
$58,660 to $33,463 for those with and without metastasis respectively
[10]. In addition, the total cost for an incident cohort of thyroid cancer
diagnosed in 2010 was approximately $1.4 billion and this number is
projected to increase to more than $2.38 billion for the 2019 cohort. The
total medical cost including diagnosis, treatment and management for
the cohorts diagnosed between 2010 and 2019 is approximately $18.59
billion dollars. A recent study by Iadeluca et al. (2017) using different US
data sources including Medical Expenditure Panel Survey (MEPS) 2011
data estimated the annual direct spending for thyroid cancer to be $5.4
billion (2011 US dollars) [11]. Another study using the SEER data con-
ducted a stacked cohort cost analysis from 1985-2013 to estimate current
and future healthcare expenditures attributable to well-differentiated
thyroid cancer (WDTC) [12]. This study conducted by Lubitz et al.
(2014) estimated the current societal costs of WDTC to be $1.6 billion in
2013 and predicted the future costs to be $3.5 billion in 2030 based on
present incidence trends [12].
The existing studies on thyroid cancer expenditures does not provide
a holistic view of the different factors associated with the excess expen-
ditures. For example, the Aschebrook-Kilfoy et al. (2013) [10] study did
not compare the healthcare expenditures of individuals with thyroid
cancer with other controls. The Lubitz et al. (2014) [12] study focused
speciﬁcally on the WDTC while the Iadeluca et al. (2017) [11] study only
provided an annual estimate of the thyroid cancer expenditure. None of
these studies examined the effect of co-occurring chronic conditions,
health and functional status on healthcare expenditures among in-
dividuals with thyroid cancer. Assessing the impact of these factors on
healthcare expenditures is important as existing literature has demon-
strated the signiﬁcant inﬂuence of these factors on healthcare use and
expenditures [13, 14, 15, 16, 17, 18, 19]. Thus, the primary objectives of
this study were to assess the excess healthcare expenditures (total and
subtypes) and factors associated with it among a nationally representa-
tive sample of community-dwelling adults with thyroid cancer compared
to non-cancer controls in the United States (US). Additionally we are
presenting the total and subtypes of out-of-pocket (OOP) expenditures as
well as OOP as a percentage of household income, which has not been
reported any of the existing studies and will be helpful to understand the
thyroid cancer burden on individuals as well their families.
2. Materials and methods
The data used in this study was publically available. Data can be
downloaded from: https://meps.ahrq.gov/mepsweb/data_stats/down
load_data_ﬁles.jsp.
2.1. Study design and study sample
We adopted a retrospective, cross-sectional, matched case-control
study design by pooling MEPS data from 2002 through 2012. We were
not able to use MEPS data post 2012 despite being available due to
change in coding system that did not allow for proper identiﬁcation of
adults with thyroid cancer. The study sample comprised of (i) adults aged
18 years or above; (ii) alive during the calendar year; and (iii) reported
positive healthcare expenditure. We identiﬁed adults with thyroid cancer2with Clinical Classiﬁcation System (CCS) code of “36” (Cancer of thy-
roid). Crosswalk of CCS and International Classiﬁcation of Diseases,
Ninth Revision, Clinical Modiﬁcation (ICD-9-CM) codes is published
online by the Agency for Healthcare Research and Quality (AHRQ) [20].
The case group consisted of adults with only thyroid cancer (no other
form of cancer). The control group consisted of adults who did not have
any form of cancer and met all the study inclusion criteria. As the case
and control group in this study are inherently different, we matched
these two groups based on propensity score to minimize the chances of
selection bias and make them comparable. Propensity score was gener-
ated based on age, gender, race/ethnicity, smoking status and Body Mass
Index (BMI). These characteristics were chosen to match the two groups,
as existing literature suggests that these characteristics are independent
predictors of thyroid cancer [21, 22, 23, 24, 25]. Each case was matched
to three controls (1:3) on propensity score using 8 to 1 greedy matching
algorithm [26]. In the greedy matching algorithm, the case group (adults
with thyroid cancer) is randomly selected at ﬁrst followed by selecting
the control subject (adults without any form of cancer) whose propensity
score is closest to that of this randomly selected case. A similar iterative
approach is used until all case group subjects are matched to control
group subjects or until there are no other case group subjects left for
whom a matched control group subject can be located. The reason for
calling this process a “greedy” algorithm is because the nearest control
group subject is selected for matching to the given case group subject,
despite the possibility of that control group subject to better serve as a
match for a subsequent case group subject [27]. Optimal matching al-
gorithm, in which matches are formed to minimize the total within-pair
difference of the propensity score, is a possible alternative to greedy
matching [27]. We selected the greedy matching algorithm for our study
over the optimal matching algorithm as an existing study [28] comparing
these two algorithms found that optimal matching did no better than
greedy matching in producing balanced matched samples and we have
successfully implemented the greedy matching algorithm for several of
our existing studies [29, 30, 31, 32, 33]. Certain co-occurring chronic
conditions (such as diabetes [34]) are independent risk factor for thyroid
cancer, but was not included in matching as this study assessed the
impact of these co-occurring chronic conditions on healthcare expendi-
tures among individuals with thyroid cancer. To demonstrate the balance
between the case and control group post matching, we estimated the
standardized mean differences (SMD) of the covariates on which the
matching was conducted. While there is not a general consensus about
the threshold of SMD, but based on prior literature we considered SMD
<0.1 to demonstrate good balance between the case and control group
after matching [35, 36]. The University of Arizona Institutional Review
Board designated this study as “Human Subjects Review Not Required”.
2.2. Data source
We used publicly available MEPS (2002–2012) data for the purpose
of this study [37]. MEPS data is collected by AHRQ and is a nationally
representative survey of the US civilian noninstitutionalized population
[38]. Sampling framework of the National Health Interview Survey
(NHIS) is used by MEPS and to achieve nationally representative esti-
mates, MEPS oversamples minority groups and individuals with dis-
abilities [39]. We used the household component and medical conditions
ﬁles of MEPS for this study. The household component consists data on
demographics characteristics, health status, healthcare expenditure,
healthcare service use, health insurance, employment, and incomes. The
medical conditions ﬁle consists of self-reported data of each participant's
medical conditions, which were coded using either CCS or ICD-9-CM
diagnosis codes. The household and medical conditions ﬁles were
merged using a unique identiﬁer (DUPERSID).
2.3. Dependent variables
Total healthcare expenditure constituted the primary dependent
S. Bhattacharjee et al. Heliyon 5 (2019) e01995variable of this study. Total healthcare expenditure was calculated as a
sum of inpatient, outpatient, emergency room visits, prescribed medi-
cation use, home healthcare, and other (dental, vision, and other medical
equipment and services) expenditures. Expenditure subtypes (such as
inpatient, outpatient) were also a part of the dependent variable.
Healthcare expenditures in this study were reported from various sources
such as direct payments from individuals, private insurance, Medicare,
Medicaid, Workers' Compensation, and miscellaneous other sources
[40]. We also calculated the total and subtypes of OOP expenditures as
well as OOP as a percentage of household income. Expenditures in this
study were expressed in terms of 2012 US dollars (constant dollars) and
were adjusted using themedical component of the annual consumer price
index (CPI) obtained from the Bureau of Labor Statistics [41]. We
transformed the expenditure data logarithmically in order to meet
normality assumption of OLS, as the expenditure data was skewed.
2.4. Independent variables
We used the Ronal M. Andersen's Behavioral Model (ABM) of Health
Services Use as a conceptual framework for this study [42]. The ABM
consists of predisposing, enabling, need, healthcare environment and
personal health practices factors, which inﬂuence healthcare use and
expenditures. The independent variables used in this study were: age,
gender, race/ethnicity, marital status, education, region, health insur-
ance status, poverty status, MEPS year, activities of daily living (ADL),
instrumental activities of daily living (IADL), functional disability, ac-
tivities disability, perceived physical health status, perceived mental
health status, BMI and co-occurring conditions. The speciﬁc chronic
co-occurring conditions were identiﬁed using ICD-9-CM and CCS. The
conditions included anxiety (CCS: 651); arthritis (CCS: 201–204);
emphysema (CCS: 127 or ICD-9-CM: 491,492, 493, 496); type II diabetes
(CCS: 49, 50); eye problems (CCS: 86, 88); gastroesophageal reﬂux dis-
ease or GERD (CCS: 138); heart diseases such as coronary heart disease,
angina, myocardial infarction (CCS: 96, 97, 100–108); hypertension
(CCS: 98, 99); depression (CCS: 69 or ICD-9-CM: 296, 311); osteoporosis
(CCS: 206); stroke (ICD-9-CM: 430–438) and thyroid disorders (CCS: 48)
[20].
2.5. Statistical analyses
We used t-tests to compare the mean healthcare expenditures be-
tween adults with thyroid cancer compared to matched controls. We
compared the distribution of the predisposing, enabling, need, personal
health practices and environmental factors before and after propensity
score matching between adults with thyroid cancer and matched controls
using chi-square test. We checked for the assumptions of Ordinal Least
Square (OLS) regression such as independence of observations, homo-
scedasticity, linearity of parameters, and multi-collinearity for the loga-
rithmically transformed expenditures. All these assumptions were met by
the logarithmically transformed expenditure variables. An a-priori alpha
of 0.05 was considered as the level of signiﬁcance in all analyses. We
conducted a series of OLS regressions on logarithmically transformed
expenditures to elucidate the inﬂuence of different factors on healthcare
expenditures among adults with thyroid cancer. In the ﬁrst OLS regres-
sion model (Model 1), we adjusted for thyroid cancer, marital status,
education, region, health insurance status, poverty status, and MEPS
year. In the second OLS regression model (Model 2), we adjusted for ADL,
IADL, functional disability, activities disability, perceived physical and
mental health status in addition to the factors in Model 1. We adjusted for
co-occurring chronic conditions in addition to the factors in Model 2 for
the third OLS regression model (Model 3). We used semi-logarithmic
equation (eβ – 1) to calculate the percent difference in costs between
adults with thyroid cancer and matched controls [43]. We adjusted for
the complex survey design of MEPS in all analyses to obtain nationally
representative estimates [38]. We conducted all analyses using survey
procedures in SAS version 9.4 software (SAS Institute Inc., Cary, NC,3USA).
3. Results
3.1. Study sample
Using MEPS 2002–2012 data, we had 208 adults with thyroid cancer
and 176,202 adults without any form of cancer, who met all the study
inclusion criteria before propensity score matching. Due to the high
sample size of the non-cancer control group, we matched 208 adults with
thyroid cancer to 624 adults without cancer based on propensity score,
without losing sample from the case group. Table 1 presents the differ-
ences in individual level characteristics before and after propensity score
matching. Prior to propensity score matching, the two groups were
signiﬁcantly different in terms of gender, poverty status, perceived
physical and mental health status, IADL limitations, co-occurring chronic
conditions and smoking status. Before matching, the proportion of fe-
males was higher in the thyroid cancer (70.9% vs. 55.8%) group
compared to non-cancer control group. A greater proportion of adults
with thyroid cancer reported higher income (52.1% vs. 42.6%), and fair
or poor physical (18.8% vs. 13.6%) health status compared to non-cancer
controls prior to matching. In terms of co-occurring chronic conditions,
adults with thyroid cancer reported a higher proportion of eye disorders
(8.3% vs. 3.7%), gastroesophageal reﬂux disorder (GERD) (16.7% vs.
7.4%), hypertension (42.4% vs. 26.1%), and thyroid disorders (26.1% vs.
7.4%) compared to non-cancer controls. A greater proportion of adult
non-cancer controls reported being current smoker (19.0% vs. 11.6%)
compared to adults with thyroid cancer. After propensity score matching,
there were no statistically signiﬁcant difference between adults with
thyroid cancer and propensity score matched non-cancer controls in
terms of gender and smoking status. However, signiﬁcant differences
existed after matching between the two groups in terms of poverty status,
perceived physical and mental health status and some co-occurring
chronic conditions. Figs. 1 and 2 exhibits the distribution of propensity
score before and after matching respectively. Fig. 2 demonstrates the
balance between the two groups after propensity score matching. The
SMDs of gender, race/ethnicity, smoking status, and BMI were zero and
that of the age groupwas 0.01, signifying that the case and control groups
were well balanced in terms of the matching covariates (see Table 2).
3.2. Expenditures
Table 3 provides the mean total and sub-types of expenditures
(inpatient, ER, outpatient, prescription drugs, home healthcare, and
other) along with standard errors among adults with thyroid cancer
compared to non-cancer controls after propensity score matching. The
yearly average total healthcare expenditures among adults with thyroid
cancer was signiﬁcantly higher compared to propensity score matched
controls ($9,585 vs. $5,830, p< 0.001). Similar observations were found
in terms of inpatient ($3,126 vs. $1,460, p < 0.05), and outpatient
($4,133 vs. $1,825, p < 0.001) expenditures. Even though we did not
observe signiﬁcant differences in terms of prescription expenditures in
sub-types of expenditure, however, prescription expenditure was signif-
icant in the OLS models. The yearly average total OOP expenditure for
adults with thyroid cancer was signiﬁcantly higher compared to matched
controls ($1,425 vs. $974, p< 0.001), with major differences observed in
inpatient OOP ($178 vs. $24, p¼ 0.003), outpatient OOP ($435vs. $256,
p < 0.001), and prescription OOP ($554 vs. $423, p < 0.001) expendi-
tures (data not shown in tabular form). There was a signiﬁcant (p <
0.001) difference between the average OOP as a percentage of household
income between adults with thyroid cancer (Mean: 7.54%, S.E: 1.52%)
and matched controls (Mean: 5.80%, S.E: 0.47%) (data not shown in
tabular form).
Table 1
Characteristics of study sample before and after Propensity Score matching MEPS
2002–2012.
Before matching After matching
Thyroid
cancer
No
cancer
Thyroid
cancer
No
cancer
Wt. % Wt. % Sig Wt. % Wt. % Sig
Predisposing factors
Age group
18–64 84.8 83.1 84.8 82.3
65,þ 15.2 16.9 15.2 17.7
Gender
Female 70.9 55.8 ** 70.9 70.7
Men 29.1 44.2 29.1 29.3
Race/Ethnicity
White 79.6 71.7 79.6 78.5
Other 20.4 28.3 20.4 21.5
Enabling factors
Marital status
Married 62.1 56.1 62.1 56.2
Other 37.9 43.9 37.9 43.8
Education
LT HS 12.0 15.8 12.0 12.5
HS 24.5 30.1 24.5 30.5
> HS 63.5 54.1 63.5 56.9
Poverty status
Poor 5.1 10.6 * 5.1 8.0 *
Near Poor 16.9 16.4 16.9 16.8
Middle Income 25.9 30.4 25.9 34.3
High Income 52.1 42.6 52.1 40.9
Employment status
Employed 72.8 68.3 72.8 66.6
Not employed 27.2 31.7 27.2 33.4
Insurance
Private 78.9 73.8 78.9 73.3
Public 10.8 16.0 10.8 17.0
Uninsured 10.4 10.2 10.4 9.6
Need factors
Perceived Physical Health status
Ex/vgood 41.6 58.0 *** 41.6 57.5 ***
Good 39.6 28.3 39.6 26.4
Fair/poor 18.8 13.6 18.8 16.1
Perceived Mental Health status
Ex/vgood 59.3 67.1 * 59.3 61.7 *
Good 35.1 25.1 35.1 27.9
Fair/poor 5.7 7.8 5.7 10.4
ADL Limitations
Yes 1.9 2.7 1.9 3.2
No 98.1 97.3 98.1 96.8
(Contd.)
IADL Limitations
Yes 2.6 5.4 2.6 6.9 **
No 97.4 94.6 97.4 93.1
Activities disability
Yes 11.9 13.3 11.9 14.7
No 88.1 86.7 88.1 85.3
Functional disability
Yes 29.1 26.2 29.1 27.0
No 70.9 73.8 70.9 73.0
Chronic conditions
Anxiety 4.4 9.9 * 4.4 11.6 ***
Arthritis 25.3 20.9 25.3 19.2
Asthma 5.1 5.9 5.1 6.6
Emphysema 9.2 10.5 9.2 9.1
Diabetes 14.8 9.8 14.8 10.2
Eye problems 8.3 3.7 * 8.3 4.2
GERD 16.7 7.4 *** 16.7 8.0 **
Heart disease 15.4 10.9 15.4 10.9
Hypertension 42.4 26.1 *** 42.4 25.6 ***
Depression 14.6 11.3 14.6 14.4
Osteoporosis 2.0 2.0 2.0 1.2
Stroke 1.4 1.5 1.4 1.8
Thyroid
disorders
26.1 7.4 *** 26.1 9.8 ***
Personal Health Practices
BMI statusy
Table 1 (continued )
Before matching After matching
Thyroid
cancer
No
cancer
Thyroid
cancer
No
cancer
Wt. % Wt. % Sig Wt. % Wt. % Sig
Under or
Normal
34.7 35.9 34.7 36.3
Overweight 29.0 33.9 29.0 33.6
Obese 31.6 28.4 31.6 26.8
Smoking status
Current
smoker
11.6 19.0 * 11.6 13.8
Other 88.4 81.0 88.4 86.2
External Environmental characteristics
Metropolitan status
Metro 82.2 83.0 82.2 84.4
Rural 17.8 17.0 17.8 15.6
Region
Northeast 24.2 18.7 24.2 16.6
Mid-west 16.6 23.3 16.6 25.1
South 40.5 35.7 40.5 35.3
West 18.8 22.3 18.8 23.0
Note: Based on 208 thyroid cancer survivors and 176,202 adults without cancer
before matching; and 208 thyroid cancer survivors and 624 adults without cancer
after matching among adults aged 18 years or older. The two groups were
matched on age, gender, race/ethnicity, smoking status and body mass index.
Asterisks represent statistical signiﬁcance between the two groups based on chi-
square tests.
Abbreviations: MEPS: Medical Expenditure Panel Survey; Wt%: Weighted per-
centage; Sig: signiﬁcant difference; Ex/vgood: excellent or very good; LT HS: less
than high school; HS: high school; ADL: Activity of Daily Living; IADL: Instru-
mental Activity of Daily; GERD: Gastroesophageal Reﬂux Disorder.
***p < 0.001; ** 0.001  p < 0.01; *0.01  p < 0.05.
y Numbers do not add up to total numbers due to missing data.
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43.3. Inﬂuence of different characteristics on expenditures
Table 4 demonstrates ﬁndings from the three different OLS regression
models. In Model 1, when we adjusted for thyroid cancer, marital status,
education, region, health insurance status, poverty status, and MEPS
year, we observed that adults with thyroid cancer had 184%, 133%,
453% and 575% higher expenditures compared to propensity score
matched non-cancer controls in terms of total, inpatient, outpatient and
prescription expenditures respectively. In Model 2, when we adjusted for
ADL, IADL, functional disability, activities disability, perceived physical
and mental health status in addition to the characteristics in Model 1, we
observed consistent ﬁndings, however, the incremental percentage dif-
ferences decreased across different expenditure types. In the ﬁnal model
(Model 3), when we adjusted for co-occurring chronic conditions over
and above the characteristics in Model 2, we observed similar ﬁndings
but the incremental expenditures reduced further. For example, incre-
mental expenditures in Model 3 compared to Model 2 were as follows:
total expenditures (88% vs. 129%), inpatient expenditures (78% vs.
97%), outpatient expenditures (230% vs. 323%), and prescription ex-
penditures (180% vs. 348%). The full Model 3 is presented in Table 5.
4. Discussion
This study presents economic burden among community-dwelling
adult thyroid cancer survivors in the US. Findings from this propensity
score matched analysis demonstrated signiﬁcantly higher economic
burden among adults with thyroid cancer compared to matched controls
in terms of average total, inpatient, outpatient, and prescription drug
expenditures. Multivariate analyses revealed that several factors
including gender, education, region, health insurance status, poverty
status, ADL, functional disability, and co morbidities have signiﬁcant
inﬂuence on healthcare expenditures among adults with thyroid cancer.
There is a dearth of literature available on economic burden of
Fig. 1. Propensity score distribution before matching. Note: Thyroid Cancer ¼ 1 denotes the case group (Thyroid Cancer survivors); Thyroid Cancer ¼ 2 denotes the
control group.
Fig. 2. Propensity score distribution after matching. Note: Thyroid Cancer ¼ 1 denotes the case group (Thyroid Cancer survivors); Thyroid Cancer ¼ 2 denotes the
control group.
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penditures are available in the US [10, 11, 12]. In our study, we reported
the actual average yearly cost per patient with thyroid cancer residing in
US communities. Furthermore, we also evaluated the impact of several
factors including socioeconomic condition, mental and physical health
and co-occurring chronic conditions on healthcare expenditures.5Moreover, we are presenting the total and subtypes of out-of-pocket
(OOP) expenditures as well as OOP as a percentage of household income.
Findings from this study suggest that outpatient expenditure among
adults with thyroid cancer was one of the major contributors (accounting
for nearly 43%) towards total healthcare expenditures. The high outpa-
tient costs are explained by excellent prognosis of thyroid cancer. The 10-
Table 2
Standardized Mean Differences (SMDs) between case and control group after
matching.
Variables Standardized Mean Differences (SMDs)
Age group 0.01
Gender 0.00
Race/Ethnicity 0.00
Smoking status 0.00
Body Mass Index status 0.00
Table 3
Mean total and types of expenditures (2012 US dollars) and standard errors of
adults with Thyroid cancer compared to non-cancer controls after propensity
score matching MEPS 2002–2012.
Thyroid cancer (N ¼ 208) Non-cancer (N ¼ 624)
Mean S.E. Mean S.E. Sig
Total 9,585 1,087 5,830 597 ***
Inpatient 3,126 678 1,460 344 *
ER 179 64 157 22
Outpatient 4,133 795 1,825 135 ***
Prescription 1,587 139 1,319 91
Other 488 72 459 46
Note: Based on 208 thyroid cancer survivors and 624 adults without cancer after
matching among adults aged 18 years or older. The two groups were matched on
age, gender, race/ethnicity, smoking status and body mass index.
Asterisks represent statistical signiﬁcance between the two groups based on t-
tests.
Abbreviations: S.E.: Standard Error; Sig: Signiﬁcant; ER: Emergency Room; HHA:
Home Health Agency.
***p < 0.001; ** 0.001  p < 0.01; *0.01  p < 0.05.
Expressed in 2012 US Dollars.
Table 4
Intercepts and parameter estimates for thyroid cancer from separate OLS regressions
Model 1 Model 2
Beta S.E. Sig % Diff Beta
Total
Intercept 6.350 0.033 *** 5.984
Thyroid cancer 1.043 0.124 *** 184 0.827
No cancer 0.000 0.000 0.000
Inpatient
Intercept 0.705 0.043 *** 0.329
Thyroid cancer 0.846 0.251 *** 133 0.679
No cancer 0.000 0.000 0.000
Outpatient
Intercept 3.685 0.056 *** 3.286
Thyroid cancer 1.710 0.181 *** 453 1.442
No cancer 0.000 0.000 0.000
Prescription
Intercept 3.505 0.068 *** 3.094
Thyroid cancer 1.910 0.126 *** 575 1.500
No cancer 0.000 0.000 0.000
Note: Based on 208 thyroid cancer survivors and 624 adults without cancer after match
race/ethnicity, smoking status and body mass index. Emergency room and Home He
icantly different between these two groups.
Asterisks represent statistical signiﬁcance between thyroid cancer and matched non-
Model 1 included thyroid cancer, marital status, education, region, health insurance
Model 2 included thyroid cancer, marital status, education, region, health insuranc
disability, perceived physical health status, and perceived mental health status as ind
Model 3 included thyroid cancer, marital status, education, region, health insuranc
disability, perceived physical health status, perceived mental health status and co-oc
S.E.: Standard Error.
***p < 0.001; ** 0.001  p < 0.01; *0.01  p < 0.05.
Sig: signiﬁcant.
% Diff: Percent difference between thyroid cancer and matched non-cancer control
calculated using semi-logarithmic equation (eβ – 1).
Abbreviations: OLS: Ordinary Least Squares.
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6year disease-speciﬁc mortality that is associated with differentiated
thyroid carcinoma is less than 5%. It is well established that initial stage
of the cancer predicts overall survival in thyroid cancer patients. Fortu-
nately, stage 1 and 2 represent 75% of all patients with thyroid disease.
This high number is easily explained by inspection of American Joint
Committee on Cancer/TNM Classiﬁcation of Malignant Tumours (AJCC/
TNM) classiﬁcation that allocates all patient less than 45 years to stage 1
or 2 regardless of extent of disease [44]. Such a high survival rate
mandates close surveillance of large population of thyroid cancer survi-
vors. After curative thyroidectomy and radio-iodine ablation (RAI)
treatment, these patients require Thyroid Stimulating Hormone (TSH)
suppression therapy and measurement of serial thyroglobulin levels and
TSH levels. Often, expensive imaging modalities such as neck Ultraso-
nography and MRI, Chest CT, RAI whole body scan and ﬂuorodeox-
yglucose (FDG)-positron emission tomography-(PET) are also necessary.
The observed inpatient expenditures were also close to outpatient
expenditures (accounting for nearly 33%) which may reﬂect the cost of
primary treatment modality (i.e. surgery) and administration of RAI for
treating cancer and management of complications from treatment
including surgery, radiation and chemotherapeutic medications
requiring hospitalization. However, it should be emphasized that
chemotherapy is rarely needed for treatment of differentiated thyroid
cancers except for RAI-refractory disease.
Our study ﬁndings suggest that the total OOP as well as inpatient,
outpatient and prescription OOP were higher among adults with thyroid
cancer compared to matched non-cancer controls. While this is a unique
addition from our study ﬁndings in the realms of thyroid cancer expen-
ditures but this ﬁnding is intuitive. A recent report by the American
Cancer Society Cancer Action Network (ACS CAN), estimated that the
OOP for cancer treatment is approximately $4 billion (2014 data) [45].
Several factors that may be associated with high OOP burden among
individuals with cancer include unforeseen and unmanageableon logged healthcare expenditures (2012 US dollars) MEPS 2002–2012.
Model 3
S.E. Sig % Diff Beta S.E. Sig % Diff
0.032 *** 7.723 0.052 ***
0.112 *** 129 0.633 0.119 *** 88
0.000 0.000 0.000
0.046 *** 2.541 0.153 ***
0.238 ** 97 0.575 0.237 * 78
0.000 0.000 0.000
0.056 *** 5.276 0.083 ***
0.166 *** 323 1.195 0.172 *** 230
0.000 0.000 0.000
0.065 *** 5.897 0.088 ***
0.117 *** 348 1.028 0.153 *** 180
0.000 0.000 0.000
ing among adults aged 18 or older. The two groups were matched on age, gender,
alth Agency expenditures are not presented as they were not statistically signif-
cancer controls based on t-tests.
status, poverty status, and MEPS year as independent variables.
e status, poverty status, MEPS year, ADL, IADL, functional disability, activities
ependent variables.
e status, poverty status, MEPS year, ADL, IADL, functional disability, activities
curring conditions as independent variables.
s groups. The percent difference in expenditures between the two groups were
Table 5
Intercepts and parameter estimates for Thyroid Cancer from Ordinary Least Square Regressions on logged healthcare expenditures (2012 US dollars) for the full model
(Model 3) Medical Expenditure Panel Survey (2002–2012).
Total Expenditures Inpatient Expenditures Outpatient Expenditures Prescription Expenditures
Beta S.E. Sig Beta S.E. Sig Beta S.E. Sig Beta S.E. Sig
Intercept 7.723 0.052 *** 2.541 0.153 *** 5.276 0.083 *** 5.897 0.088 ***
Thyroid cancer
Yes 0.633 0.119 *** 0.575 0.237 * 1.195 0.172 *** 1.028 0.153 ***
No 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
ADL limitations
Yes 0.354 0.029 *** 0.816 0.093 *** 0.256 0.046 *** 0.042 0.047
No 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
IADL limitations
Yes 0.174 0.023 *** 0.410 0.063 *** 0.143 0.037 *** 0.145 0.037 ***
No 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
Activities disability
Yes 0.389 0.017 *** 0.476 0.039 *** 0.410 0.026 *** 0.348 0.028 ***
No 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
Functional disability
Yes 0.282 0.011 *** 0.050 0.021 * 0.445 0.020 *** 0.394 0.022 ***
No 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
Perceived physical health status
Excellent/Very Good 0.216 0.011 *** 0.202 0.021 *** 0.278 0.018 *** 0.442 0.019 ***
Fair/Poor 0.196 0.014 *** 0.468 0.035 *** 0.184 0.021 *** 0.105 0.022 ***
Good 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
Perceived mental health status
Excellent/Very Good 0.040 0.011 *** 0.076 0.023 *** 0.056 0.019 ** 0.001 0.019
Fair/Poor 0.022 0.017 0.098 0.042 * 0.064 0.028 * 0.060 0.029 *
Good 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
Marital status
Married 0.137 0.009 *** 0.151 0.016 *** 0.261 0.017 *** 0.208 0.017 ***
Others 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
Education
> HS 0.281 0.012 *** 0.061 0.023 ** 0.459 0.023 *** 0.263 0.022 ***
HS 0.129 0.013 *** 0.042 0.025 0.184 0.023 *** 0.146 0.023 ***
< HS 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
Metropolitan status
Metropolitan 0.013 0.014 0.009 0.024 0.011 0.028 0.152 0.031 ***
Rural 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
Region
Mid-west 0.110 0.015 *** 0.111 0.023 *** 0.111 0.028 *** 0.288 0.030 ***
Northeast 0.084 0.018 *** 0.025 0.025 0.151 0.031 *** 0.218 0.036 ***
South 0.010 0.014 0.098 0.022 *** 0.079 0.029 ** 0.402 0.030 ***
West 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
Income
High Income 0.219 0.016 *** 0.386 0.029 *** 0.362 0.027 *** 0.262 0.029 ***
Middle Income 0.046 0.015 ** 0.303 0.028 *** 0.168 0.026 *** 0.055 0.025 *
Near Poor 0.003 0.015 0.167 0.028 *** 0.054 0.025 * 0.016 0.025
Poor 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
Insurance
Private 0.811 0.015 *** 0.365 0.023 *** 1.306 0.028 *** 0.808 0.028 ***
Public 0.784 0.018 *** 0.568 0.031 *** 1.249 0.032 *** 0.918 0.032 ***
Uninsured 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
Anemia
Yes 0.486 0.031 *** 1.273 0.097 *** 0.752 0.040 *** 0.275 0.050 ***
No 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
Anxiety
Yes 0.320 0.014 *** 0.015 0.029 0.495 0.023 *** 0.823 0.027 ***
No 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
Asthma
Yes 0.142 0.023 *** 0.008 0.055 0.134 0.035 *** 0.513 0.042 ***
No 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
Arthritis
Yes 0.322 0.010 *** 0.023 0.023 0.662 0.017 *** 0.475 0.019 ***
No 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
Emphysema
Yes 0.227 0.017 *** 0.085 0.040 * 0.470 0.027 *** 0.741 0.028 ***
No 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
Diabetes
Yes 0.443 0.013 *** 0.144 0.035 *** 0.301 0.021 *** 1.198 0.021 ***
No 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
Eye problems
Yes 0.507 0.017 *** 0.039 0.049 1.041 0.026 *** 0.694 0.029 ***
No 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
GERD
Yes 0.537 0.014 *** 0.178 0.037 *** 0.520 0.024 *** 1.227 0.024 ***
No 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
(continued on next page)
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Table 5 (continued )
Total Expenditures Inpatient Expenditures Outpatient Expenditures Prescription Expenditures
Beta S.E. Sig Beta S.E. Sig Beta S.E. Sig Beta S.E. Sig
Heart disease
Yes 0.613 0.012 *** 1.010 0.037 *** 0.656 0.019 *** 0.704 0.021 ***
No 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
Hypertension
Yes 0.449 0.010 *** 0.049 0.022 * 0.498 0.016 *** 1.705 0.016 ***
No 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
Depression
Yes 0.432 0.013 *** 0.120 0.029 *** 0.557 0.022 *** 1.114 0.024 ***
No 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
Osteoporosis
Yes 0.486 0.022 *** 0.040 0.066 0.712 0.035 *** 1.133 0.041 ***
No 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
Stroke
Yes 0.353 0.031 *** 1.210 0.120 *** 0.091 0.045 * 0.224 0.050 ***
No 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
Thyroid disorders
Yes 0.386 0.013 *** 0.034 0.033 0.653 0.023 *** 1.055 0.021 ***
No 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
MEPS year 0.032 0.002 *** 0.014 0.003 *** 0.020 0.003 *** 0.091 0.003 ***
Note: Based on 208 thyroid cancer survivors and 624 adults without cancer after matching among adults aged 18 or older. The two groups were matched on age, gender,
race/ethnicity, smoking status and body mass index. Emergency room and Home Health Agency expenditures are not presented as they were not statistically signif-
icantly different between these two groups.
Asterisks represent statistical signiﬁcance between thyroid cancer and matched non-cancer controls based on t-tests.
Model 3 included thyroid cancer, marital status, education, region, health insurance status, poverty status, MEPS year, ADL, IADL, functional disability, activities
disability, perceived physical health status, perceived mental health status and co-occurring conditions as independent variables.
S.E.: Standard Error.
***p < 0.001; ** 0.001  p < 0.01; *0.01  p < 0.05.
Sig: signiﬁcant.
Abbreviations: ADL: Activities of Daily Limitations; IADL: Instrumental Activities of Daily Limitations; OLS: Ordinary Least Squares; GERD: Gastroesophageal Reﬂux
Disease; MEPS: Medical Expenditure Panel Survey.
S. Bhattacharjee et al. Heliyon 5 (2019) e01995expenditures such as requiring a treatment not covered by their plan,
high co-insurance and deductibles, as well as possibility of seeking
out-of-network care [45]. A study examining the associations between
OOP costs and reduced and/or delayed treatment initiation observed that
higher OOP costs were associated with higher rates of oral prescription
abandonment and delayed initiation across cancers [46]. While the ACS
CAN report [45] and the study by Doshi et al. (2018) [46] provide data
from a general cancer perspective, but these issues are applicable to the
higher OOP burden among thyroid cancer survivors and their families. In
the light of the OOP burden discussion, it can be implied that ﬁnancially
viable strategies such as limits on OOP costs are required to minimize this
high OOP burden among cancer survivors and their families.
Findings of OLS regression models suggest that after adjusting for
health and functional status and co-occurring chronic conditions, the
excess expenditure percentage of total healthcare reduced signiﬁcantly.
Existing studies suggest that fair or poor physical and mental health
status [18] as well as functional limitations [19] lead to a high healthcare
use and expenditures. Moreover, existence of a liner correlation between
cancer and mental health status decline has been observed [14] that can
lead to poor quality of life, medication non-compliance and increase risk
of mortality [15]. All these negative outcomes generally lead to increased
expenditure, which supports the ﬁnding of this study that mental and
physical health status and co-occurring chronic conditions signiﬁcantly
inﬂuence healthcare expenditures among individuals with thyroid can-
cer. It implies that effective therapeutic approach should emphasize on
optimization of co-occurring chronic conditions as well as physical and
mental health for individuals with thyroid cancer. This is particularly
true in the setting of thyroid cancer with high survival rate. The
cancer-speciﬁc survival of patients with papillary thyroid cancer
conﬁned to the thyroid gland was 97% at 20 years even without treat-
ment [47]. Although majority of these patients will not die from thyroid
cancer, they live with the psychological burden of a cancer diagnosis.
These ﬁndings suggest that multidisciplinary approach is needed for
close surveillance of individuals with thyroid cancer that includes the8oncologist, primary care physician, pharmacist, clinical psychologist,
physical and occupational therapists. It can signiﬁcantly mitigate the
economic burden in these patients. The Patient-Centered Medical Home
(PCMH) is one of the noteworthy models of care that can serve thyroid
cancer survivors well by promoting preventive services, providing ho-
listic care and long-term surveillance post thyroid cancer treatment.
Some of the strengths of this study include the use of a robust study
design such as the propensity score matching that helps to make the case
(thyroid cancer) and control (non-cancer) comparable on observable
charateristics. Moreover, this study provides estimates at national-level
among community-dwelling adults with thyroid cancer and uses
several key factors such as ADL, IADL, perceived physical and mental
health status which have been shown to be independent predcitors of
healthcare expenditure among cancer patients but is usually not available
in other datasets. However, limitations of this study should be kept in
mind while interpreting the ﬁndings. In this study, thyroid cancer was
treated as a single entity, but histologically it is characterized into
different types such as well differentiated papillary cancer with an
excellent survival rate and anaplastic thyroid cancer with extremely poor
prognosis. However, It should be recognized that most thyroid cancer is
papillary thyroid carcinoma (accounts for approximately 85% of thyroid
cancer cases) and therefore the fact that we have not accounted for
different types is of lesser concern. This study did not have the following
information in the MEPS database: stage of cancer detection, procedures
performed, nature of care provider or specialty that can be used to
examine difference as per hospital ratings or reputations, as well as in-
formation on cases of abandonment or relapse or death. Other limitations
of this study include small sample sizeand not including recent treatment
modalities such as new targeted therapies.
5. Conclusions
Given the rapid rate of increase in prevalence of thyroid cancer, it
remains a signiﬁcant clinical and economic burden on healthcare system.
S. Bhattacharjee et al. Heliyon 5 (2019) e01995In addition to development of new diagnostic and therapeutic strategies,
we should also focus on psychosocial impact of thyroid cancer that can
signiﬁcantly reduce the economic burden in this patient population.
Moreover, it is also imperative that rigorous approach should be opted to
treat the co-occurring chronic conditions. These measures mandate the
organized efforts by a multidisciplinary team involved in the patient care.
And ﬁnally, ﬁnancially viable strategies such as limits on OOP costs are
required to minimize this high OOP burden among cancer survivors and
their families.
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